EU Annex 1 in Practice: How a CDMO Builds a Modern Sterile Fill/Finish Facility

Annex 1 details the requirements for manufacturing sterile pharmaceutical products intended for distribution in the European Union. Many of the principles and standards included are consistent with expectations from other regulatory bodies, including the US Food and Drug Administration (FDA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). As such, Annex 1 is widely used as a key reference when designing sterile manufacturing for global markets, particularly for aseptic processing.

As sterility testing is a destructive process, sterility of the entire batch is not possible. Therefore, the principles of sterile (or aseptic) processing must be designed into the manufacturing of the product and adhered to throughout the entirety of the operation. Annex 1 and FDA guidance both emphasize that sterility and other critical quality attributes cannot be assured by terminal processing or finished product testing alone. Quality and sterility cannot be “tested into” the product.

Annex 1’s Principle states that “the manufacture of sterile products is subject to special requirements in order to minimize risks of microbial, particulate and endotoxin/pyrogen contamination.” The Pharmaceutical Quality System (PQS) for aseptic products must include:

• Risk management is integrated into all areas of the product life cycle, with application to the Contamination Control Strategy (CCS), documented with rationales.
• Investigation of excursions (procedural, process, or equipment failures, test failures, environmental monitoring divergences) commensurate with risk to determine root causes with appropriate CAPAs.
• Senior management ensures an overall state of control throughout the product life cycle.
• Personnel responsible for product release have access to all necessary records and adequate knowledge.

The CCS must be formally documented, implemented across the facility and actively reviewed, incorporating plant and process design, equipment, personnel, materials, risk management, monitoring systems, and continuous improvement.

Sterile products using aseptic processing should be manufactured in cleanrooms designed to minimize contamination. Annex 1 defines four grades:

• Grade A – the cleanest (“critical”) zone, where the highest-risk operations (open container filling, stoppering) occur
• Grade B – background for Grade A, where some aseptic preparation can be completed
• Grades C and D – for less critical steps, such as equipment preparation before sterilization

An air pressure gradient ensures that during any breach, air always travels from cleaner areas into less clean zones. All cleanrooms must be made of smooth, impervious materials to minimize particle shedding and prevent crevices where microorganisms may collect. Materials must withstand cleaning and disinfection agents without deterioration.

Air flow should be filtered and adequate to flush contaminants out of the room. Air must not flow from less clean areas or over operators into higher grade or more critical areas. Air flow patterns should be visualized (e.g., with “smoke studies”) to ensure these requirements are met.

Material entry in high-grade areas should follow unidirectional, controlled, and validated transfer processes. Where appropriate, this may include double-door sterilizers or other validated transfer systems.  Airlocks should operate so both doors are never opened simultaneously.

All equipment must be fit-for-purpose; able to reliably perform its function without introducing contamination. Equipment must be made of appropriate materials with smooth, easily cleanable surfaces, with functionality verified and qualified. Utilities systems should be designed, qualified, operated, maintained, and monitored to ensure they function as intended and do not compromise product quality.

Water for Injection (WFI)

WFI should be produced by distillation or a method resulting in equivalent purity, with key design features including:

• Storage tanks vented with bacterially retentive hydrophobic filters
• Distribution legs built to maintain minimum temperatures to prevent microbial growth
• Designed to avoid dead legs, with piping sloped for complete draining
• Turbulent flow within distribution legs to minimize microbial adhesion to pipe walls

Systems should be disinfected, sterilized, or regenerated routinely and monitored regularly, with data analyzed to detect potential trends.

Steam and Process Gases: Annex 1 Sterilization and Filtration Requirements

Steam used for sterilization must have condensate meeting WFI chemical purity requirements, with physical attributes (non-condensable gases, dryness fraction, superheat) regularly assessed. Gases in direct product contact should be filtered through 0.22 𝜇m or smaller filters or filters otherwise qualified to provide equivalent microbial retention to retain microbial contaminants.

In modern cleanrooms, humans are by far the largest source of potential contamination. Only the minimum number of operators necessary should be present. All operators must be trained and qualified on proper gowning and cleanroom behavior, with data regularly collected and a process for disqualification in the event of negative monitoring trends.

Gowns for Grade A or B areas should be sterile and completely cover the operator, including head and face. Sterile gloves should be regularly disinfected and changed immediately if damaged.

Movements should be slow and controlled to minimize particulate generation. Operators must never position themselves upwind of critical areas—air passing over operators must not be allowed into critical areas. Airflow visualization studies should be performed with operators performing expected actions during routine activities.

The environmental monitoring (EM) and process monitoring program represent parts of the CCS. No individual element should be considered an indicator of sterility. Rather, the entire data set should be reviewed as standard practice. The EM and process monitoring program should, at a minimum, contain:

• Total airborne particle levels
• Viable (microbial growth) particle levels (airborne, surface, and operator)
• Temperature, humidity, and differential pressure
• Process simulations (media fills) for aseptic manufacture

Sampling locations, frequencies, and methods should be determined based on risk assessment and reviewed periodically.

Aseptic Process Simulations (Media Fills)

Aseptic process simulations using microbial growth medium as a proxy for product demonstrate that the process is designed to prevent contamination. Simulations should follow standard manufacturing as closely as possible, incorporating all aseptic operations and inherent and corrective interventions, challenging worst-case conditions (e.g. container size, line speed, maximum hold times, number of operators).

Aseptic process simulations should include a sufficient number of units to provide a meaningful, statistically justified challenge to the aseptic process, taking into account line speed, container type, and process risk. The target for all aseptic process simulations should be zero growth. Any positive unit should trigger a thorough investigation to determine the most probable root causes, appropriate corrective actions, and the impact on all products produced since the last successful simulation. Site procedures should define acceptance criteria and any need to repeat or expand simulations, justified based on risk, process history, and applicable regulatory guidance.

Sponsors should perform suitable audits on CDMO partners to ensure full compliance. Evidence of Annex 1 alignment should include:

• Facility qualification: Documentation showing validated critical areas with smoke studies demonstrating airflow patterns and pressure differential monitoring with alarms
• Contamination Control Strategy: Documented, risk-based CCS actively maintained and connected to operational practices
• Utilities governance: Validated water, steam, and gas systems with monitoring and trending
• Personnel qualification: Training records on aseptic behavior and gowning with individual performance monitoring
• PQS governance: Evidence that Quality Risk Management informs decisions throughout operations

Annex 1 represents extensive guidance on aseptic manufacturing for products supplied to the European Union and is widely used as a reference when designing global sterile operations. Incorporating risk assessment and management into all aspects of manufacturing, validating all critical operations, and maintaining strict focus on contamination control can all be applied globally.